Latest advances in the management of radiation-induced pain flare, nausea and vomiting

Ann Palliat Med. 2016 Jan;5(1):50-7. doi: 10.3978/j.issn.2224-5820.2015.08.01.

Abstract

Palliative radiotherapy (RT) is an effective treatment for symptomatic bone metastases. However, pain flare, nausea and vomiting are common adverse effects associated with this treatment. The management of pain flare and radiation-induced nausea and vomiting (RINV) are important endpoints in palliative care. Our report documents the incidence, clinical importance, and advances in the management of these two adverse-effects. We recommend that antiemetic prophylaxis be given based on emetic risk category as outlined in the American Society of Clinical Oncology (ASCO) guidelines. Newer antiemetics investigated in the chemotherapy setting should also be studied in the radiation setting. As there are no guidelines for the use of pain flare prophylaxis at present, further research in this area is needed.

Keywords: Antiemetics; nausea; pain flare; radiation; vomiting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiemetics / therapeutic use*
  • Bone Neoplasms / radiotherapy*
  • Bone Neoplasms / secondary
  • Dexamethasone / therapeutic use
  • Humans
  • Methylprednisolone / therapeutic use
  • Musculoskeletal Pain / prevention & control*
  • Nausea / prevention & control*
  • Ondansetron / therapeutic use
  • Palliative Care / methods
  • Radiotherapy / adverse effects
  • Serotonin 5-HT3 Receptor Antagonists / therapeutic use
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Serotonin 5-HT3 Receptor Antagonists
  • Ondansetron
  • Dexamethasone
  • Methylprednisolone